The collaboration between BioMed X and Novo Nordisk marks a significant step forward in the field of drug delivery, specifically targeting the oral administration of therapeutic peptides. This partnership is set to explore novel formulation technologies that promise to enhance the absorption and bioavailability of peptide-based drugs, a challenge that has long hindered the effectiveness of oral peptide therapeutics.
The project, titled 'Prolonged Retention of Oral Peptide Formulations in the Gut,' will focus on developing technologies that ensure tablets or capsules remain in the lower small intestine for an extended period. This approach aims to overcome the current limitations of low intestinal permeability and rapid gastrointestinal transit, which significantly reduce the efficacy of oral peptide formulations.
Dr. Christian Tidona, CEO of BioMed X, expressed enthusiasm about the partnership, highlighting the potential impact on patients' lives. The collaboration leverages BioMed X's unique crowdsourcing approach and Novo Nordisk's expertise in oral peptide formulation, including the launch of the first oral biologic on the market.
Stephen Buckley, Scientific Vice President at Novo Nordisk, emphasized the company's commitment to pushing the boundaries of science through both internal and external innovation. This project represents a shared vision to advance the field of oral peptide drug delivery, with the ultimate goal of improving patient outcomes.
Researchers interested in contributing to this groundbreaking project are encouraged to submit their proposals via the BioMed X Career Space before October 12, 2025. This initiative not only underscores the importance of collaborative research in addressing complex biomedical challenges but also highlights the potential for significant advancements in drug delivery technologies.
